Blog
RSS FeedPosted by Michael Wonder on 26 Feb 2025
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection (final guidance)
26 February 2025 - NICE has published final evidence-based recommendations on the use of osimertinib mesylate (Tagrisso) for the adjuvant ...
Posted by Michael Wonder on 21 Feb 2025
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
20 February 2025 - Final guidance published today recommends lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) as an option for treating ...
Posted by Michael Wonder on 19 Feb 2025
Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 19 Feb 2025
Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with etoposide ...
Posted by Michael Wonder on 13 Feb 2025
Olaparib for the treatment of patients with advanced, BRCA mutation positive, HER2 negative breast cancer after chemotherapy
12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...
Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 12 Feb 2025
Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder
12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...
Posted by Michael Wonder on 05 Feb 2025
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)
5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...
Posted by Michael Wonder on 05 Feb 2025
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)
5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...
Posted by Michael Wonder on 23 Jan 2025
Vadadustat for the treatment of adults with symptomatic anaemia on dialysis for chronic kidney disease
23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...
Posted by Michael Wonder on 21 Jan 2025
NICE has made six times more lung cancer treatment recommendations over the past ten years than in the previous decade
21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...
Posted by Michael Wonder on 10 Jan 2025
Erdafitinib for the treatment of patients with metastatic or unresectable FGFR altered urothelial cancer
9 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 10 Jan 2025
Tebentafusp for the treatment of patients with advanced uveal melanoma
9 January 2025 - NICE has published final evidence-based recommendations on the use of tebentafusp (Kimmtrak) for the treatment of ...
Posted by Michael Wonder on 23 Dec 2024
Over 1,000 people with advanced breast cancer set to benefit from new once a day tablet
19 December 2024 - We’ve issued final draft guidance recommending a new once a day tablet that is set to benefit ...